INDICATION

ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Triple-Class Exposed* Patients Experienced Superior Efficacy With ABECMA®1

Demonstrated superior PFS vs 5 standard regimens after 2L treatment2

Progression-free Survival in ITT Population Graph Progression-free Survival in ITT Population Graph
Months    ABECMA     Standard regimens
0   254   132
3   206   75
6   178   42
9   149   32
12   110   25
15   62   13
18   40   20
21   22   7
24   14   6
27   4   2
30   2   1
33   0   0
  • Primary PFS analysis: Median PFS of 13.3 months (95% CI, 11.8-16.1) with ABECMA vs 4.4 months with standard regimens (95% CI, 3.4-5.9); HR=0.49 (95% CI, 0.38-0.64); P<0.0001 at 15.9 months of follow-up3†
  • Final PFS analysis: Median PFS of 13.8 months (95% CI, 11.8-16.1) with ABECMA vs 4.4 months with standard regimens (95% CI, 3.4-5.8); HR=0.49 (95% CI, 0.38-0.63); at 30.9 months of follow-up2,4
  • Patients in the control arm received the following therapies: DPd (33%), EPd (24%), Kd (22%), IRd (16%), DVd (6%)1

The efficacy analysis was performed on the ITT population of all randomized patients.5

Patients who have received an immunomodulatory agent, a PI, and an anti-CD38 monoclonal antibody.3

The primary efficacy analysis was performed on the ITT population of all randomized patients. For patients randomized to the ABECMA arm (n=254), this included 24 patients who were leukapheresed but did not receive ABECMA. For patients randomized to the standard regimens arm (n=132), this included 6 patients who did not receive treatment.5

2L=second-line; CI=confidence interval; DPd=daratumumab, pomalidomide, dexamethasone; DVd=daratumumab, bortezomib, dexamethasone; EPd=elotuzumab, pomalidomide, dexamethasone; HR=hazard ratio; IRd=ixazomib, lenalidomide, dexamethasone; ITT=intention to treat; Kd=carfilzomib, dexamethasone; PFS=progression-free survival.


Identify your
ABECMA-eligible patients

Start the ABECMA
process faster
than
ever—find a certified
treatment center
near you